Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
Patients 60 to 70 years of age with newly diagnosed multiple myeloma were prospectively
randomized between 4 cycles of anthracycline/dexamethasone-based induction chemotherapy (A1)
or only 2 x 4 days of dexamethasone (A2). A reference arm included patients who could not be
randomized (B). Tandem melphalan 140 mg/m² (MEL140) with autologous transplantation was
scheduled for all patients.